The text provides unaudited financial information for Bristol-Myers Squibb Company, including consolidated statements of earnings, comprehensive income, balance sheets, and cash flows. It also discusses the company's basis of consolidation, recent accounting standards, business segment information, use of estimates and judgments, and revenue breakdown by nature and product/region. The company's financial highlights for the year include net product sales, earnings, expenses, and comprehensive income. Key figures for the company's financial performance are provided for the three and six months ended June 30, 2023 and 2022. The company operates in a single segment dedicated to the discovery, development, and marketing of innovative medicines. The text also includes detailed financial information and disclosures for a business entity involving various financial instruments, debt obligations, derivative contracts, hedges, equity, and other assets and liabilities. It includes data on hedge transactions, swaps, debt maturity and repayment, credit facilities, receivables, inventories, property, plant and equipment, goodwill, intangible assets, income taxes, and other financial details of the company. Additionally, it reports on equity changes, dividends, share repurchases, and stock compensation for the relevant periods.
The text provided is a detailed Management's Discussion and Analysis of Financial Condition and Results of Operations for a pharmaceutical company. The company outlines its main strategies, revenue changes, expenses, earnings per share, economic and market factors affecting their operations, product approvals, the process of estimating end-user demand, financial position and liquidity, capital resources, cash flow activities, critical accounting policies, forward-looking statements, and risks associated with future performance. Key elements include updates on marketed products, recent drug approvals, financial data, and explanations of critical accounting policies used by the company.
Refer to the 2022 Form 10-K for discussion about market risk, found under "Item 7A: Quantitative and Qualitative Disclosures about Market Risk."
Management evaluated the design and operation of its disclosure controls and procedures, concluding they were effective as of June 30, 2023. There were no significant changes in the Company's internal control over financial reporting during the quarter that have materially impacted or are likely to affect the Company's financial control.
The text provides a brief mention of where to find information related to legal proceedings in the financial statements, specifically in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies."
The text provided states that there have been no significant changes in the risk factors disclosed in the company's 2022 Form 10-K.
The text provides a summary of the unregistered sales of equity securities and the use of proceeds during the three months ending June 30, 2023. The table outlines the total number of shares purchased, average price paid per share, shares purchased as part of announced programs, and the remaining dollar value of shares that can be purchased under the program. It also mentions the authorization by the Board of Directors for repurchase of common stock up to $6.0 billion as of June 30, 2023, as part of the share repurchase program.
I am ready to receive the text for summarization.
I'm ready to help once you provide the text you wish to be summarized. Please go ahead and share the text with me.
During the period covered in the quarterly report, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement. At the 2023 Annual Meeting of Shareholders, a say-on-frequency advisory vote was conducted regarding named executive officer compensation, resulting in a determination for an annual basis for such votes by the company's Board of Directors, as recommended in the proxy statement for the meeting.
The text provides a list of exhibits related to a Quarterly Report on Form 10-Q, including certification letters and XBRL documents. It also includes a summary of terms and abbreviations related to the filing, as well as trademarks associated with certain products. The document is signed by the Chairman of the Board and Chief Executive Officer, as well as the Chief Financial Officer of Bristol-Myers Squibb Company.
